IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
-
Narrated by:
-
By:
About this listen
Featuring an interview with Dr Patrick Y Wen, including the following topics:
- Glioma classification (0:00)
- Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50)
- Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55)
- Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46)
- Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30)
- Current and emergent strategies for the management of glioblastoma (31:27)
- Optimizing patient care and quality of life (46:24)
CME information and select publications
No reviews yet